Liquidity & Technicals
Liquidity & Technicals
Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
Liquidity is the binding constraint on this name. Reported daily turnover averages just $16,500, which means a 5% portfolio position clears in five trading days only for funds under roughly $343,000 in AUM — too small for any institutional mandate. Beneath that wall, the tape is bearish: price sits 21% below the 200-day moving average with a fresh death cross on 13-Feb-2026, an 85% drawdown from the 2022 peak, and realized volatility in the 80th percentile of its five-year range.
1. Portfolio implementation verdict
5-day capacity at 20% ADV ($)
Largest 5d position (% mkt cap)
Supported fund AUM, 5% wt ($)
ADV 20d / Mkt Cap (%)
Technical score (-6 to +6)
Not institutionally implementable. ADV is 0.025% of market cap. A 0.5% issuer-level position would take roughly 98 trading days to exit at 20% ADV participation; a 1% position takes 196 days. The largest position that genuinely clears in five sessions at 20% ADV is roughly 0.026% of market cap — meaningless for any fund of size. Build is only possible for specialist microcap mandates willing to accumulate over 60+ trading days; for everyone else this is a watchlist name at best, regardless of view.
2. Price snapshot
Last close ($)
YTD return (%)
1-year return (%)
52-week position (percentile)
3-year return (%)
The stock is roughly 24% of the way up its 52-week range — far closer to the $0.130 low than to the $0.377 high. From the all-time high of $1.43 set in late 2022, the share price has shed about 85%. The Numbers tab flagged margin compression and earnings deterioration; the tape is fully consistent with that, with no sign of a sponsorship rebuild.
3. Critical chart — full price history with 50/200 SMA
Death cross active since 13-Feb-2026. Current price $0.189 is 21.2% below the 200-day moving average ($0.240) and below the 50-day average ($0.172). This is an unambiguous downtrend — not "mixed", not "consolidating".
The 10-year history shows three regimes: a multi-year base sub-$0.025 through 2018, a 50× re-rating to a $1.43 peak in October 2022 (formulation-portfolio expansion narrative), and a 30-month decline that has now retraced more than 85% of that gain. Seven golden crosses and seven death crosses since 2019 reflect the whipsaw character of an underowned microcap; the cross signal is noisier here than in liquid names, but the alignment of price below both medium- and long-term averages does carry weight.
4. Relative strength (company, rebased)
No comparable Indian equity benchmark or sector ETF was loaded for this run, so a direct relative-strength panel against Nifty or an agrochemicals index is not available. The chart above shows the company line in isolation — a roughly 75% absolute decline over three years that, against a Nifty 50 that compounded mid-single-digits over the same period, implies cumulative relative underperformance of more than 80 percentage points.
5. Momentum panel — RSI(14) + MACD histogram
RSI is 56, squarely neutral, but with a clear downward slope from 75+ readings in November 2025 — overbought conditions then have unwound, with no oversold capitulation yet. MACD has just flipped positive (histogram +0.07) on the 28-Apr-2026 sma_20-vs-50 golden cross, indicating a short-term mean-reversion bounce inside a larger downtrend. The signal is consistent: short-term momentum is improving from washout, but the 200-day picture is unchanged. Bouncing inside a downtrend is the most common false-positive in microcap tapes; treat it as a relief rally until price reclaims $0.240.
6. Volume, volatility, and sponsorship
Volume is the most damning piece of the technical evidence. The 50-day average traded volume of roughly 90,000 shares is well below the trailing-year norm and there is no visible footprint of accumulation: the November 2025 32x volume spike was followed by a 25% decline over the next three weeks, which reads as distribution not absorption. Realized 30-day volatility sits at 58.8% annualized — at the 80th percentile of the five-year band (p20 = 29%, p80 = 60%). Combined with a median 60-day daily range of 5.03%, every meaningful order will print impact cost. The market is pricing a wider risk premium than at any point in the last 18 months.
7. Institutional liquidity panel
This name is not institutionally tradable under conventional participation limits. The data manifest tags it as not-illiquid because mid-cap-style sanity checks pass, but applying a real fund-sizing lens — five-day clear, 20% ADV ceiling — exposes the constraint immediately.
A. ADV and turnover strip
ADV 20d (shares)
ADV 20d ($)
ADV 60d (shares)
ADV 20d / Mkt Cap (%)
Annual turnover (%)
For context, an institutionally tradable Indian small-cap normally clears 50%–150% annual turnover. Best Agrolife clears 6.5%, putting it in the bottom decile of investable Indian equities by float velocity.
B. Fund-capacity table — what fund AUM does this stock support?
Read this row by row: at the conventional buy-side ceiling of 20% ADV participation, a 5% portfolio position is implementable for funds up to $343,000 AUM. At a stricter 10% ADV cap, that ceiling drops to $172,000. These are essentially HNI-individual scales, not institutional ones.
C. Liquidation runway — days to exit a hypothetical issuer-level position
A meaningful institutional exit is multi-month even at the smallest position tier. A 1%-of-market-cap position takes roughly nine and a half months to unwind at 20% ADV — long enough for the fundamental thesis to break before the trade is fully out.
D. Intraday range proxy
The 60-day median intraday range is 5.03% (high to low, expressed as a percentage of close). For comparison, large-cap Indian names typically print 1.5%–2%. A median range above 2% is the threshold above which we flag elevated impact cost; this stock is more than double that. Combined with thin ADV, it produces a meaningful execution discount on top of the headline technical picture: even patient algo execution will leave a measurable price footprint.
The bottom line: the largest issuer-level position that clears in five sessions at 20% ADV is 0.026% of market cap (~$17,170); at 10% ADV, 0.013% (~$8,585). Liquidity is the bottleneck, not technicals.
8. Technical scorecard and 3-6 month stance
Stance — bearish on a 3-to-6-month horizon. The fundamental erosion flagged in the Numbers tab is mirrored cleanly in the tape: a sub-200-day downtrend with weak volume, stressed volatility, and no relative-strength relief. The current MACD bounce is a counter-trend rally and should be sold, not faded into. The bullish invalidation is a daily close above $0.240 (the 200-day SMA), held for ten sessions; that would also restore the 50-vs-200 alignment. The bearish confirmation is a daily close below $0.130 (the 52-week low), which would clear the floor of the entire 2024-2026 trading range and target the next structural support near $0.084.
Liquidity is the constraint. Even readers who want to fade the bounce or buy the eventual washout cannot do so at institutional size. The correct action for any fund larger than roughly $0.5M AUM is avoid. Specialist microcap mandates can build only via patient absorption over 60+ trading sessions, and only if the price first reclaims the 200-day to confirm regime change.